We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
Join our family
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
Register for Drug Discovery & Development Symposium 2025
The PVRI Drug Discovery and Development Symposium 2025 #DDDS2025 will be taking place on 16-17 June 2025 in Amsterdam. See our event page for more details and register your place!
A PH Group III webinar. Presentations: Is there evidence for different phenotypes of PH in ILD? Treatment of pulmonary vascular disease in ILD: as early as possible or only in severe PH?
Perspectives on Global Epidemiology Challenges is part of the Microbes Virtual Symposium series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.
Webinar presentations: Cardiopulmonary networks: bridging infection and microbiome in pulmonary vascular disease; Inflammasome activation in pulmonary arterial hypertension; Role of oxidative signals in endothelial phenotypes in PH; Spironolactone: an old drug with new tricks; HIPPO/MST signaling via BUB3 and FOXO drives pulmonary vascular cell growth and survival
Resting heart rate has been incorporated in REVEAL risk assessment. Rest and sleep heart rate variability (HRV) measured in the home setting could provide early insight into worsening physiology in patients with pulmonary arterial hypertension (PAH).
Although current guidelines recommend standard cardiopulmonary exercise testing (CPET) to evaluate symptomatic patients after pulmonary embolism (PE), CPET with simultaneous echocardiography could provide relevant information to evaluate right ventricular–pulmonary arterial coupling.
Treatment patterns of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in Finland are unknown. Guidelines now recommend early escalation of treatment for PAH. We evaluated how well Finnish practice follows guidelines, and how treatment initiations and outcomes are related.
The PVRI 2025 Annual Congress was hosted in the vibrant city of Rio de Janeiro at the Windsor Convention & Expo Centre. Esteemed experts, healthcare professionals, and researchers from around the globe gathered in this iconic city to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering PVD.
Rubin Tuder, a trailblazer in the field of pulmonary vascular biology and a driving force in PH research, has been honoured with the PVRI Lifetime Achievement Award for 2025. This prestigious Award is given annually at the PVRI Annual Congress to a senior PH investigator or clinician for their exceptional and outstanding contributions to the field of pulmonary vascular disease and to PVRI. This recognition celebrates his unparalleled contributions to science, mentorship, and the global PH community.
The Burke Advanced Fellowship in Pulmonary Heart Disease at The Brigham and Women’s Hospital and Harvard Medical School—invites applications for an advanced fellowship in pulmonary heart disease starting July 1, 2026. This training program is sponsored by the Center for Pulmonary Heart Disease at the Brigham and Women’s Hospital. The position offers an intensive clinical experience including evaluation and management of both inpatients and outpatients with pulmonary vascular disease and right heart dysfunction or failure. In addition, applicants are strongly encouraged to participate in a translational or clinical research program.
We are excited to announce that registration is open for the PVRI Drug Discovery and Development Symposium 2025! #DDDS2025 will be taking place 16-17 June 2025 in Amsterdam and promises to be an excellent opportunity for regulatory, industry, and academic bodies to meet and discuss the latest drug developments in PH.